Association between sedative prescriptions after hospital discharge and falls and other adverse events in older adults: a population-based cohort study Authors: Lisa D Burry, Louise Rose, Ruxandra Pinto, David R Williamson, Andrea Hill, Damon Scales, Susan E Bronskill, Robert Fowler, Lisa Dolovich, Longdi Fu, Chaim M Bell, Hannah Wunsch Published: 2026 ABSTRACT AbstractBackground:Whether sedative prescriptions after hospital admissions are associated with poor patient outcomes is unknown. We sought to determine the incidence and risk of adverse events associated with sedatives in older adults within 30 days after hospital discharge.Methods:We conducted a population-based cohort study involving older adults (age ≥ 66 yr) discharged alive from hospital in Ontario (2003 to 2023). We assessed the association of sedative prescriptions (benzodiazepines, antidepressant sedatives, or antipsychotics) filled within 7 days after discharge with falls (with or without fracture), emergency department (ED) visits, and hospital readmission. We used cause-specific proportional hazard regression for outcomes other than death and Cox proportional hazard models for death to assess the association between a sedative prescription filled after discharge and the outcomes. Because of an interaction with prehospital sedative prescription, we stratified results for prehospital sedative-naive and sedative-exposed status.Results:Among 1 868 484 older adults (mean age 77 yr, 52.1% female), 13.2% filled a sedative prescription after discharge; of these patients, 31.0% were sedative naive before hospital admission. Falls occurred in 1.6% (n = 30 626), ED visits in 21.3% (n = 397 402), hospital readmissions in 12.4% (n = 231 191), and death in 3.8% (n = 70 661). The adjusted hazard ratio (HR) for all outcomes was increased among those who filled a sedative prescription after discharge (v. no filled prescription) and were sedative naive before hospital admission (fall: 1.20, 95% confidence interval [CI] 1.13 to 1.26; ED visit 1.20, 95% CI 1.19 to 1.22; hospital readmission: 1.20, 95% CI 1.17 to 1.22; and death: 1.78, 95% CI 1.73 to 1.83). For those who were exposed to sedatives before their hospital admission, there was an increased hazard of death (adjusted HR 1.08, 95% CI 1.05 to 1.11), but not for the other outcomes. For sedative-naive older adults, benzodiazepines were associated with an increased hazard of all outcomes, antipsychotics were associated with an increased hazard of falls and death, and antidepressant sedatives were associated with a decreased hazard of falls.Interpretation:New sedative prescriptions filled within 7 days after discharge were associated with increased hazards of a fall, ED visit, hospital admission, and death within 30 days after discharge, with differences based on the sedative class. These findings have important implications for in-hospital medication review and falls-risk assessment for older adults in Canada. Prescribing potentially inappropriate medications for older adults is discouraged, as medications with limited effectiveness in this population may be associated with adverse events, resulting in harm or requiring additional health care services.1–4 Sedatives and antipsychotics are listed as potentially inappropriate medications because of their known association with adverse events.1–4 Serious adverse events associated with their use in older adults living at home, in community settings, or in long-term care facilities include falls, fractures, delirium, cognitive impairment, and death.5–9 In hospitals, sedatives and antipsychotics are frequently prescribed for patients to facilitate diagnostic or therapeutic interventions, as well as to manage sleep disturbances, anxiety, and delirium.10–12 The initiation of sedative and antipsychotic prescriptions in hospital is generally intended for short-term use while the patient is in hospital. However, in population-based studies, 3% to 10% of older adults in North America, Europe, and Asia who were not prescribed these medications before hospital admission (i.e., prehospital sedative naive) filled a new benzodiazepine or antipsychotic prescription at or shortly after hospital discharge.13–15 Although adverse events associated with the initiation of sedatives or antipsychotics (e.g., falls) have been well described in community-dwelling and long-term care older adult populations,5–9,16–22 the risks to patients who continue new hospital-initiated sedative and antipsychotic prescriptions after hospital discharge are unknown, as are the risks associated with chronic home sedative or antipsychotic prescriptions after hospital discharge. The association with adverse events may differ between new use and chronic use because of physiologic changes (e.g., organ dysfunction and altered drug metabolism) or debilitation from an acute illness requiring hospital admission. Given the widespread use of these medications in hospital, it is important to investigate the associated risks with their use after hospital discharge to inform discharge prescribing practices. We sought to determine the incidence and risk of serious adverse events, specifically falls requiring medical attention, emergency department (ED) visits, hospital readmission, and death, associated with a new or continued sedative prescription among older adults during the first 30 days after hospital discharge. Methods Design and setting We conducted a population-based cohort study using health care, prescription, and administrative data available at ICES (www.ices.on.ca) for the province of Ontario, Canada. ICES is an independent, nonprofit research institute whose legal status under Ontario’s health information privacy law allows it to collect and analyze health and demographic data without consent, for the purpose of evaluating and improving the health system. The province of Ontario publicly funds hospital and physician care for all residents (approximately 16 million), including outpatient prescriptions for those aged 65 years and older. We linked databases at the individual patient level using unique encoded identifiers at ICES (Appendix 1, Table E1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.251965/tab-related-content). The missing rate for data used in this study was less than 0.5%. Our analysis plan was registered with the Open Science Framework (Apr. 11, 2023). We followed the Strengthening the Reporting of Observational Studies in Epidemiology and Reporting of Studies Conducted Using Observational Routinely-Collected Health Data for Pharmacoepidemiology statements for study reporting (Appendix 1, Table E2). Study population We included all adults aged 66 years and older who were discharged alive from an acute care hospital admission between Apr. 1, 2003, and Aug. 31, 2023. We restricted cohort entry to age 66 years and older at the hospital discharge date (hospital discharge date = index date) to permit a 180-day look-back in the outpatient prescription claims database (Ontario Drug Benefit [ODB]) for prehospital prescription medication exposures. We excluded hospital admissions with missing or invalid provincial health card numbers, missing age or age older than 105 years at the index date, missing sex, hospital length of stay of 1 day or less, and hospital admissions with a prior admission in the 180 days before the admission date (as we could not confirm sedative exposure in ODB while a patient was in hospital).23 Additionally, we excluded hospital admissions after which patients were discharged to inpatient facilities that do not submit prescription claims to ODB, such as facilities for palliative care, rehabilitation, or mental health. For patients with more than 1 hospital admission who met the inclusion criteria, we selected 1 admission at random for inclusion. Exposures The primary exposure was any sedative prescription filled within 7 days after hospital discharge. This time window has been used in similar epidemiologic studies and supports the attribution of a filled prescription to the hospital encounter.13,24 Our definition of a sedative prescription, based on market availability, prescribing practices, and the ODB formulary, was a benzodiazepine, an antidepressant sedative (specifically, mirtazapine and trazodone), or an antipsychotic, dispensed for any dose or duration (see Appendix 1, Table E3 for a full list of medications).13 Nonbenzodiazepine Z-drug (e.g., zopiclone, zolpidem, zaleplon) sedative–hypnotics were not eligible for reimbursement under the ODB at any point in the study; therefore, we could not include them in our analysis. Outcomes The primary outcome was a fall, with or without a fracture, that resulted in medical attention within 30 days after hospital discharge (i.e., documented in the ED, outpatient setting [including hospital- or community-based ambulatory care services, day surgery, outpatient, and community-based clinic services], or hospital records). These have excellent positive predictive value (0.91 for falls; 0.81 to 0.96 for fractures, depending on fracture site).25 Secondary outcomes were all-cause ED visits, hospital readmissions, and death within 30 days after hospital discharge.25,26 The data sources and diagnostic codes used to identify each outcome have been previously described and validated (Appendix 1, Table E3).17,25,27–29 Statistical analysis We identified the following patient-level characteristics at the index date: age, sex, neighbourhood median income quintile, Deyo-adapted Charlson Comorbidity Index (categorized as 0, 1–2, ≥ 3),30 John Hopkins Adjusted Clinical Group System frailty markers in version 10 (binary),31 and the presence of conditions associated with falls in the published literature — specifically, dementia, Parkinson disease, osteoporosis, alcoholism, and history of falls that received medical attention in the last year. We identified in-hospital therapies or diagnoses, including surgery; acute kidney injury; receipt of renal replacement therapy; sepsis; stroke; intensive care unit (ICU) admission; billing for geriatric, palliative, or psychiatry services; length of hospital stay; hospital discharge destination; and year of hospital discharge. We assessed for other medication exposures associated with falls (i.e., anticonvulsants, antidepressants [other than mirtazapine and trazodone], antihypertensives, and opioids).32 For each medication class, we assessed prescriptions filled within 180 days before hospital admission to define patients as either prehospital naive or exposed. We compared characteristics of patients with and without a sedative prescription filled within 7 days after hospital discharge, stratified by prehospital sedative exposure, reporting standardized mean differences. We calculated the unadjusted incidence of each outcome of interest for the entire cohort and stratified by whether patients did or did not fill a sedative prescription within 7 days after hospital discharge. We used cumulative incidence function (CIF) curves to describe outcomes, with death as a competing risk, and the Gray test to evaluate differences in the incidence function between groups. We entered the association between a sedative prescription filled within 7 days after hospital discharge and falls, ED visits, and hospital readmission in the model as time-dependent covariates and conducted the analysis using cause-specific proportional hazard regression, with death as a competing risk and adjustment for the covariates listed above (patient-level and in-hospital therapies or diagnoses).33 We used a Cox proportional hazard model to examine the association between a sedative prescription filled within 7 days after hospital discharge and death. Follow-up time was constructed from the index date to the first event, death, or administrative censoring at 30 days. We expressed measures of association between exposure and outcome as adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). A priori, we planned to test for an interaction with prehospital prescription exposure within 180 days before hospital admission. As the interaction was significant, we presented results stratified on prehospital exposure status. We tested for an interaction with year of discharge; however, this interaction was not significant and was therefore not included in the models. We also calculated the E-value to quantify the strength of association that an unmeasured confounder would need to have with both the exposure and the outcome to nullify any identified associations.34 We conducted a sensitivity analysis by modifying the primary analysis to shorten the observation window to 14 days, as we anticipated that most adverse events would occur early after hospital discharge. We conducted additional sensitivity analyses by excluding patients who were readmitted or died within 7 days after hospital discharge and by excluding patients who had any billing for palliative care while admitted to hospital. It is possible that patients with a prehospital sedative prescription did not need to fill a prescription within 7 days after hospital discharge if they had an adequate supply available at home. We therefore conducted a post hoc sensitivity analysis to classify those who had filled a sedative prescription within 30 days before hospital admission as a patient who filled the prescription within 7 days after discharge, and set the time of prescription fill as the hospital discharge date. We assessed the following subgroups to explore differences in the association between treatment and the primary outcome: age (≤ 75 or > 75 yr), sex, surgery, ICU admission, dementia, and frailty,31 also stratifying by prehospital sedative exposure. Finally, we assessed the relationship between each sedative class and each outcome. We examined Schoenfeld residuals for proportionality assumptions (the assumptions were met). We performed analyses using SAS Enterprise Guide version 7.15 (SAS Institute) and created figures with R version 1.4. All p values reported are 2-sided, with a threshold of less than 0.05 considered significant. Ethics approval The research ethics boards of Sunnybrook Health Sciences Centre (no. 2688) and Sinai Health (no. 19–02327-C) approved the study protocol. Results From Apr. 1, 2003, to Aug. 31, 2023, 1 868 484 adults aged 66 years or older met the inclusion criteria (Figure 1). Of the cohort, 13.2% (n = 246 440) filled at least 1 sedative prescription within 7 days after hospital discharge; 31.0% (n = 76 335) of these older adults were sedative naive before hospital admission. Sedative prescriptions were primarily filled on the day of hospital discharge (median 0, interquartile range [IQR] 0 to 3, d); 33.0% of sedative prescriptions were benzodiazepines, 29.0% were antidepressant sedatives, and 38.0% were antipsychotics (Appendix 1, Table E4). Table 1 summarizes cohort characteristics stratified by prehospital sedative exposure. The mean age was 77 (standard deviation 8) years, and 52.1% of the cohort were female. Irrespective of prehospital sedative exposure, those with a sedative prescription filled within 7 days after hospital discharge were older and were more likely to have frailty and dementia. Flow chart of cohort creation for older adults (age ≥ 66 yr) admitted to hospital in Ontario from 2003 to 2023. Note: ODB = Ontario Drug Benefit. See Related Content tab for accessible version. Table 1:Characteristics of the cohort, stratified by prehospital sedative prescription exposure*CharacteristicAll patientsn = 1 868 484Sedative naiven = 1 427 848Sedative exposedn = 440 636Sedative ≤ 7 d after dischargeSMDSedative ≤ 7 d after dischargeSMDNon = 1 351 513Yesn = 76 335Non = 270 531Yesn = 170 105Age, yr, mean ± SD77.3 ± 8.076.8 ± 7.879.9 ± 8.40.3777.3 ± 7.880.1 ± 8.40.34Sex, female974 167 (52.1)660 614 (48.9)40 187 (52.6)0.08164 835 (60.9)108 531 (63.8)0.06Deyo-adapted Charlson Comorbidity Index score 0595 411 (31.9)467 203 (34.6)13 826 (18.1)0.3881 070 (30.0)33 312 (19.6)0.24 1–2781 811 (41.8)555 291 (41.1)34 349 (45.0)0.08112 672 (41.6)79 499 (46.7)0.10 ≥ 3491 262 (26.3)329 019 (24.3)28 160 (36.9)0.2776 789 (28.4)57 294 (33.7)0.11Frailty†315 414 (16.9)163 073 (12.1)21 422 (28.1)0.4150 961 (18.8)79 958 (47.0)0.63Dementia218 209 (11.7)92 712 (6.9)25 921 (34.0)0.7134 371 (12.7)66 084 (38.8)0.63Osteoporosis173 792 (9.3)121 024 (9.0)7105 (9.3)0.0127 759 (10.3)17 904 (10.5)0.01Fall in the past year‡158 671 (8.5)97 529 (7.2)8910 (11.7)0.1525 544 (9.4)26 688 (15.7)0.19History of alcoholism26 695 (1.4)16 980 (1.3)2604 (3.4)0.143849 (1.4)3262 (1.9)0.04Parkinson disease25 855 (1.4)13 777 (1.0)1586 (2.1)0.095053 (1.9)5439 (3.2)0.08Prehospital medications Polypharmacy§636 501 (34.1)366 571 (27.1)23 007 (30.1)0.07143 874 (53.2)103 049 (60.6)0.15 Anticonvulsants154 502 (8.3)92 220 (6.8)5345 (7.0)0.0130 035 (11.1)26 902 (15.8)0.14 Antidepressants¶413 443 (22.1)165 687 (12.3)13 425 (17.6)0.15125 657 (46.4)108 674 (63.9)0.36 Antihypertensives1 148 027 (61.4)816 139 (60.4)44 228 (57.9)0.05177 544 (65.6)110 116 (64.7)0.02 Opioids431 438 (23.1)260 335 (19.3)17 728 (23.2)0.1094 559 (35.0)58 816 (34.6)0.01Teaching hospital559 273 (29.9)410 751 (30.4)21 469 (28.1)0.0581 191 (30.0)45 862 (27.0)0.07Surgery726 072 (38.9)578 014 (42.8)17 203 (22.5)0.4496 821 (35.8)34 034 (20.0)0.36Sepsis or septic shock293 751 (15.7)184 907 (13.7)19 083 (25.0)0.2944 211 (16.3)45 550 (26.8)0.26ICU admission246 973 (13.2)188 271 (13.9)11 202 (14.7)0.0232 013 (11.8)15 487 (9.1)0.09Acute kidney injury146 922 (7.9)101 542 (7.5)8377 (11.0)0.1219 045 (7.0)17 958 (10.6)0.12Dialysis21 438 (1.1)15 170 (1.1)1002 (1.3)0.023358 (1.2)1908 (1.1)0.01Stroke71 376 (3.8)51 889 (3.8)4346 (5.7)0.098944 (3.3)6197 (3.6)0.02Consultation, geriatrics89 473 (4.8)50 008 (3.7)11 109 (14.6)0.3812 272 (4.5)16 084 (9.5)0.19Consultation, palliative care58 096 (3.1)27 091 (2.0)11 043 (14.5)0.479712 (3.6)10 250 (6.0)0.11Consultation, psychiatry175 874 (9.4)85 447 (6.3)22 836 (29.9)0.6423 977 (8.9)43 614 (25.6)0.46Hospital stay, d median (IQR)5 (3–9)4 (3–8)12 (6–26)0.945 (3–8)7 (4–13)0.40Discharge destination Community**1 762 966 (94.4)1 309 883 (96.9)62 820 (82.3)0.49258 086 (95.4)132 177 (77.7)0.54 Long-term care facility105 518 (5.6)41 630 (3.1)13 515 (17.7)0.4912 445 (4.6)37 928 (22.3)0.54Note: ICU = intensive care unit, IQR = interquartile range, SD = standard deviation, SMD = standardized mean difference.*Data presented as no. (%), unless stated otherwise.†John Hopkins Adjusted Clinical Group System frailty marker.‡History of falls documented in National Ambulatory Care Reporting System or Discharge Abstract Database in 1 year before hospital admission.§Polypharmacy was defined as 9 or more unique medications.¶Excludes trazodone and mirtazapine as these were considered to be sedatives.**Includes discharged home with or without support (e.g., home care) or supportive housing, correctional facility, or residential care. Characteristics of the cohort, stratified by prehospital sedative prescription exposure* Note: ICU = intensive care unit, IQR = interquartile range, SD = standard deviation, SMD = standardized mean difference. Data presented as no. (%), unless stated otherwise. John Hopkins Adjusted Clinical Group System frailty marker. History of falls documented in National Ambulatory Care Reporting System or Discharge Abstract Database in 1 year before hospital admission. Polypharmacy was defined as 9 or more unique medications. Excludes trazodone and mirtazapine as these were considered to be sedatives. Includes discharged home with or without support (e.g., home care) or supportive housing, correctional facility, or residential care. Primary outcome Within 30 days after hospital discharge, 30 626 (1.6%) older adults experienced at least 1 fall that resulted in medical attention (median time to event: 13, IQR 5 to 20, d) (Table 2). The unadjusted CIF curves showed that older adults with a sedative prescription filled within 7 days after hospital discharge (v. those without) had an increased risk of falls overall (Figure 2A). For patients who were prehospital sedative naive, we found an increased hazard of a fall for those who filled a new sedative prescription after discharge (v. those without), after adjusting for relevant covariates (adjusted HR 1.20, 95% CI 1.13 to 1.26; E-value 1.74, 95% CI 1.57 to 1.91). For those who were exposed to sedatives prehospital, we found no association with a sedative prescription filled within 7 days after hospital discharge and a fall (adjusted HR 1.00, 95% CI 0.96 to 1.05; E-value 1.31, 95% CI 1.00 to 1.62) (see Table 2 and Appendix 1, Table E5 for complete model outputs). All of our sensitivity analyses showed similar findings (Appendix 1, Table E6). Subgroup analyses showed a greater hazard of a fall for prehospital sedative-naive older adults who were younger (≤ 75 yr), were female, had an ICU admission, were admitted to the hospital for medical reasons (v. surgery), had a diagnosis of dementia, or had frailty (Figure 3). Table 2:Adverse outcomes for older adults after hospital discharge and association with sedative prescription, stratified by prehospital sedative exposure*OutcomeAll patientsn = 1 868 484Sedative naiven = 1 427 848Sedative exposedn = 440 636Sedative ≤ 7 d after dischargeSedative ≤ 7 d after dischargeNon = 1 351 513Yesn = 76 335Adjusted HR (95% CI)†‡Non = 270 531Yesn = 170 105Adjusted HR (95% CI)†‡Primary outcome Fall§30 626 (1.6)18 837 (1.4)1897 (2.5)1.20 (1.13–1.26)5070 (1.9)4822 (2.8)1.00 (0.96–1.05)Secondary outcomes ED visit397 402 (21.3)275 486 (20.4)18 804 (24.6)1.20 (1.19–1.22)62 549 (23.1)40 563 (23.8)1.01 (0.99–1.02) Hospital readmission231 191 (12.4)156 962 (11.6)12 062 (15.8)1.20 (1.17–1.22)37 451 (13.8)24 716 (14.5)0.98 (0.97–1.00) Death70 661 (3.8)35 565 (2.6)9864 (12.9)1.78 (1.74–1.83)12 209 (4.5)13 023 (7.7)1.08 (1.05–1.16)Note: CI = confidence interval, ED = emergency department, HR = hazard ratio.*Data presented as no. (%), unless stated otherwise.†For each model, the interaction test between prehospital and posthospital sedative prescription exposure was p < 0.001.‡Full model outputs are presented in Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.251965/tab-related-content. Model covariates: age (continuous); sex (male/female); income quintile; frailty (binary); history of falls (binary); osteoporosis (binary); new stroke or transient ischemic attack (binary); dementia (binary); Parkinson disease (binary); alcoholism (binary); surgery (binary); sepsis or septic shock (binary); intensive care unit admission during hospital admission (binary); acute kidney injury (binary); dialysis (binary); in-hospital consultation for geriatrics, palliative care, or psychiatry; length of hospital stay; discharge destination; year of discharge; and medications associated with increased hazard of falls (anticonvulsants, antidepressants, antihypertensives, opioids).§Includes ED visits for fall or fracture. Adverse outcomes for older adults after hospital discharge and association with sedative prescription, stratified by prehospital sedative exposure* Note: CI = confidence interval, ED = emergency department, HR = hazard ratio. Data presented as no. (%), unless stated otherwise. For each model, the interaction test between prehospital and posthospital sedative prescription exposure was p < 0.001. Full model outputs are presented in Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.251965/tab-related-content. Model covariates: age (continuous); sex (male/female); income quintile; frailty (binary); history of falls (binary); osteoporosis (binary); new stroke or transient ischemic attack (binary); dementia (binary); Parkinson disease (binary); alcoholism (binary); surgery (binary); sepsis or septic shock (binary); intensive care unit admission during hospital admission (binary); acute kidney injury (binary); dialysis (binary); in-hospital consultation for geriatrics, palliative care, or psychiatry; length of hospital stay; discharge destination; year of discharge; and medications associated with increased hazard of falls (anticonvulsants, antidepressants, antihypertensives, opioids). Includes ED visits for fall or fracture. Cumulative incidence function curve for adverse outcomes within 30 days after hospital discharge, stratified by sedative prescription filled within 7 days after hospital discharge. Gray test: p < 0.001 for each outcome. Note that the scales of the y-axes differ. Note: CI = confidence interval, ED = emergency department. Association of a fall within 30 days after hospital discharge for older adults and sedative prescription filled within 7 days after discharge, by preplanned subgroup. A hazard ratio greater than 1 means an increased risk of falls in those who filled a prescription. Note: CI = confidence interval, ICU = intensive care unit. Secondary outcomes Within 30 days after hospital discharge, 397 402 (21.3%) patients had at least 1 ED visit (time to event: median 8, IQR 4 to 16, d), 231 191 (12.4%) were readmitted to hospital (time to event: median 10, IQR 5 to 17, d), and 70 661 (3.8%) died (time to event: median 13, IQR 6 to 21, d) (Table 2). For each of these outcomes, the unadjusted CIF curves showed an increased risk for older adults with a sedative prescription filled within 7 days after hospital discharge (v. those without) (Figure 2B to 2D). For those who were prehospital sedative naive, a sedative prescription filled within 7 days after hospital discharge was associated with an increased hazard of an ED visit (adjusted HR 1.20, 95% CI 1.19 to 1.22; E-value 1.76, 95% CI 1.71 to 1.81) and hospital readmission (adjusted HR 1.20, 95% CI 1.17 to 1.22; E-value 1.71, 95% CI 1.64 to 1.78) (Table 2 and Appendix 1, Table E5). For those who were prehospital sedative exposed, we found no association with ED visit (adjusted HR 1.01, 95% CI 0.99 to 1.02; E-value 1.16, 95% CI 1.11 to 1.21) or hospital readmission (adjusted HR 0.98, 95% CI 0.97 to 1.00; E-value 1.11, 95% CI 1.00 to 1.21). We found an increased hazard of death irrespective of prehospital exposure (sedative naive: adjusted HR 1.78, 95% CI 1.73 to 1.83; E-value 2.81, 95% CI 2.71 to 2.91; sedative exposed: adjusted HR 1.08, 95% CI 1.05 to 1.11; E-value 1.21, 95% CI 1.00 to 1.42). Adverse outcomes by type of sedative For older adults with a benzodiazepine prescription, we found an increased hazard of a fall for both prehospital benzodiazepine-naive and prehospital benzodiazepine-exposed groups (adjusted HR 1.25, 95% CI 1.17 to 1.34 and adjusted HR 1.09, 95% CI 1.03 to 1.15, respectively) (Figure 4 and Appendix 1, Table E7). Those who were prehospital benzodiazepine naive had an increased hazard of an ED visit (adjusted HR 1.26, 95% CI 1.23 to 1.28), readmission (adjusted HR 1.26, 95% CI 1.23 to 1.30), and death (adjusted HR 1.57, 95% CI 1.53 to 1.62) (Appendix 1, Table E7). For older adults who filled an antipsychotic prescription who were prehospital antipsychotic naive, we found an increased hazard of falls (adjusted HR 1.10, 95% CI 1.03 to 1.18) and death (adjusted HR 1.62, 95% CI 1.58 to 1.66). We found a lower association with antidepressant sedative prescription and falls, irrespective of prehospital exposure status (prehospital naive adjusted HR 0.83, 95% CI 0.75 to 0.91; prehospital exposed adjusted HR 0.90, 95% CI 0.83 to 0.98). Association of falls and sedative prescription filled within 7 days after hospital discharge by sedative class, stratified by prehospital sedative status. Interaction terms between prehospital sedative naive and exposed status p < 0.001 for benzodiazepines and antipsychotics; p = 0.054 for antidepressant sedatives. Hazard ratios greater than 1 indicate an increased risk in those who filled a sedative prescription. See Related Content tab for accessible version. Note: CI = confidence interval. Interpretation In this cohort of 1.86 million older adults discharged alive following an acute care hospital admission, we identified that 13% filled a sedative prescription (a benzodiazepine, an antidepressant sedative, or an antipsychotic) within 7 days after hospital discharge, with approximately one-third of individuals naive to these medications before hospital admission. Our results showed that discharging older adults after an acute care hospital stay with a new prescription for these medications was associated with an increased hazard of falls requiring medical attention, further need for acute hospital care, and death in the 30 days after hospital discharge, whereas individuals with prior exposure did not experience the same increased hazards. The risk of adverse events was not consistent across all sedatives examined, with the most consistent association shown for benzodiazepines. Overall, these data suggest that the largest risk for patients centres on new benzodiazepine prescriptions, whereas continuation of prior sedatives in older adults may pose minimal risk. We selected falls requiring medical attention as our primary outcome of interest because falls are a substantial burden in health systems worldwide35 and are important to patients. Few studies have reported falls for older adults after an acute hospital admission, with only 1 study reporting on sedative exposure.36–39 Mahoney and colleagues reported that the rate of falls was highest in the first 2 weeks after hospital discharge (8/1000 person-days), with fall-related injuries accounting for 1 in 6 hospital readmissions.37 These rates are similar to our findings in the first 30 days after hospital discharge. One prospective observational study with 311 patients explored prehospital, hospital, and post-hospital factors associated with falls in older adults after hospital discharge.37 Of the psychoactive drugs investigated, only tricyclic antidepressants (e.g., amitriptyline) were associated with an increased risk of falls after hospital discharge. Our finding that falls were associated with a new sedative prescription is congruent with findings from studies in older adults living in community or in long-term care.28,32,37,40–42 However, our finding of a reduced risk of falls for trazodone or mirtazapine prescriptions was unexpected and differs from the results of published studies in other populations. Bronskill and colleagues found that the risk of fall-related injury for low-dose trazodone was not different than the risk associated with benzodiazepines in a retrospective cohort study involving 7791 long-term care residents. 17 In a retrospective cohort study of long-term care residents, Macri and colleagues found a significant association between new antidepressant prescriptions (inclusive of trazodone and mirtazapine) and falls, with an adjusted odds ratio [OR] of 1.9 (95% CI 1.7 to 2.2).43 This research group also considered the association between specific antidepressant drugs and falls, and found a significant association for trazodone (adjusted OR 1.8, 95% CI 1.4 to 2.2) but not for mirtazapine (adjusted OR 0.9, 95% CI 0.4 to 2.0). Other research groups have identified similar strong associations for trazodone.44–46 Possible reasons for our different findings include the selection of patients who receive these drugs in hospital (e.g., confounding by indication), as well as the possibility of different prescribing practices in hospital that mitigate the risk (e.g., dose initiation and titration may be slower in hospital than in the community or long-term care settings). Further work is needed to understand the clinical decisions that lead to the use of these medications by class and to confirm our findings. We found that new sedative prescriptions were significantly associated with falls, increased health care use, and all-cause death after adjusting for an extensive list of important confounders. Numerous studies have examined the association between psychoactive medications and death, with most demonstrating a similar magnitude of association, especially in patients with dementia.7,8,16,18,20–22,47–55 The association with death may reflect, in part, confounding by illness severity or indication, as sedatives may be initiated in the context of clinical deterioration, severe agitation and delirium, or evolving end-of-life trajectories that are incompletely captured in administrative data. Such confounding is likely more pronounced for death than for falls, where pharmacologic mechanisms linking sedatives to harm are biologically plausible and described. Although the overall absolute magnitude of the risk of adverse events identified was modest from a population perspective, the effects on patients and their families are clinically and socially important. Moreover, given the volume of hospital admissions among older adults and the aging population, a modest increase in risk translates into a large impact on the health care system. Patients who were sedative naive before hospital admission and were prescribed sedatives at discharge — particularly a benzodiazepine or antipsychotic — deserve particular attention from clinicians and the health care system. In addition to the Best Possible Medication History (a comprehensive, verified, and structured record of a patient’s prescription and nonprescription medications) and medication reconciliation (a formal process of using the Best Possible Medication History to compare against new orders at transitions of care and addressing any discrepancies), prescribing of these medications should prompt a structured medication review that explicitly confirms the clinical indication, dose, interaction with other medications, intended duration of therapy, and a reassessment plan. Such a review should be integrated into a falls-risk assessment in keeping with Accreditation Canada’s Required Organizational Practices56 for falls prevention and injury reduction, which expects identification and mitigation of all medication-related fall risk as part of a standardized multifactorial approach. Where feasible, nonpharmacologic strategies or short, time-limited prescriptions should be prioritized, and de-escalation or deprescribing before hospital discharge should be considered. When ongoing sedative prescription is necessary, arranging follow-up within 1 to 2 weeks after discharge to reassess need, monitor adverse effects, and formally reassess falls risk may help mitigate harm. At a health-system level, integrating automated alerts for new sedative prescriptions into electronic discharge workflows, linking medication reconciliation with formal falls-risk screening and mitigation protocols, and tracking new sedative prescribing as a quality indicator could support safer transitions of care for older adults. The distinction between new initiation and continuation of prehospital medication suggests that prevention of new sedative exposure at hospital discharge may represent the highest-yield target for intervention. Limitations In-hospital prescription data are unavailable in Ontario’s health databases. Therefore, misclassification is possible. We could not confirm whether a sedative prescription filled after hospital discharge was administered during the hospital admission, representing a continuation of a sedative received during acute illness rather than a prescription written to be started after discharge. Nor could we confirm that patients who did not fill a sedative prescription at hospital discharge were not exposed to a sedative during their hospital admission. Neither the indication nor the appropriateness of the sedative prescription, nor compliance with the filled prescription, could be confirmed from the data sets. Residual confounding by indication and illness severity is likely most relevant for the outcome of death. Because sedatives may be initiated in patients with delirium, several behavioural symptoms, or clinical deterioration that are incompletely measured in the administrative data available, the observed association with death may be more susceptible to bias. We could not study sedating medications not publicly reimbursed in Ontario, including Z-drugs, over-the-counter sedating medications (e.g., antihistamines, melatonin), and low-strength codeine that patients might pay for out of pocket. It is unclear whether our findings can be generalized to younger patients or those transferred to inpatient rehabilitation facilities for further care. Furthermore, we cannot comment on less severe falls or near misses that did not require medical attention. Future studies are needed to confirm the associations we identified between specific classes of sedatives and adverse outcomes following hospital discharge — in particular, the finding of a reduced risk of falls with antidepressant sedatives trazodone and mirtazapine. Research is also needed to explore the impact of sedative classes that we were unable to explore based on our formulary, as well as sedative polypharmacy (combinations of > 1 drug). Future intervention studies should focus on ways to improve medication reconciliation and medication review of sedatives for deprescribing or de-escalation before hospital discharge. Conclusion In this population-based cohort study of older adults discharged from an acute care hospital admission in Ontario, new sedative prescriptions filled within 7 days after discharge were associated with increased hazards of a fall, ED visit, hospital readmission, and death within 30 days after discharge, with differences based on the sedative class. Given the identified associations, clinicians must consider whether new sedative prescriptions are essential or can be deprescribed or de-escalated before or shortly after hospital discharge. When ongoing sedative use is required, community support, such as falls or mobility assessments, and ongoing medication reviews may help mitigate risks. Supplementary Information Footnotes Competing interests: Louise Rose has been awarded grants from National Institute for Health and Care Research, European Society of Intensive Care Medicine, and National Health and Medical Research Council, paid to her institution. Susan Bronskill reports grants from Canadian Institutes of Health Research (CIHR), Alzheimer Society of Canada, Brain Canada, Evaluative Clinical Sciences Platform Seed Grant, Sunnybrook Research Institute, and Public Health Agency of Canada. Dr. Bronskill also reports consultation fees from Canada’s Drug Agency. Hannah Wunsch reports grants from CIHR, paid to her institution. No other competing interests were declared. This article has been peer reviewed. Contributors: Lisa Burry and Longdi Fu had access to full data and take responsibility for the integrity of the data. Lisa Burry, Ruxandra Pinto, and Andrea Hill take responsibility for the accuracy of the data analyses. Lisa Burry, Louise Rose, and Hannah Wunsch contributed to study conception and design. The statistical plan was created by Lisa Burry, Ruxandra Pinto, and Hannah Wunsch. All authors interpreted the data. Lisa Burry drafted the manuscript, which all authors reviewed. All authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work. Lisa Burry acts as guarantor. Funding: This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). Hannah Wunsch was supported by a Canada Research Chair (Tier 2) in Critical Care Organization and Outcome. The CIHR funded the analyses (grant no. 159696). The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the manuscripts, or decision to submit for publication. Data sharing: The data set for this study is securely held in coded form at ICES. Although legal data-sharing agreements between ICES and data providers prohibit ICES from making the data set publicly available, access may be granted to those who meet prespecified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca). The full data set creation plan and underlying analytic code are available from the authors on request, understanding that the computer programs may rely on coding templates or macros that are unique to ICES and are, therefore, either inaccessible or may require modification. Disclaimer: ICES (formerly the Institute of Clinical and Evaluative Sciences) is an independent, nonprofit research institute whose legal status under Ontario’s health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health-system evaluation and improvement. As a prescribed entity under Ontario’s privacy legislation, ICES is authorized to collect and use health care data for the purposes of health system analysis, evaluation, and decision support. Secure access to these data is governed by policies and procedures that are approved by the Information and Privacy Commissioner of Ontario. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). The opinions, analyses, and conclusions expressed in this manuscript are those of the authors and do not reflect the funding or data sources. No endorsements by ICES, the MOH, MLTC, or CIHI are intended or should be inferred. The authors thank IQVIA Solutions Canada Inc. for the use of its Drug Information Database. This document used data adapted from the Statistics Canada Postal CodeOM Conversion File, which is based on data licensed from Canada Post Corporation, and/or data adapted from the Ontario Ministry of Health Postal Code Conversion File, which contains data copied under licence from Canada Post Corporation and Statistics Canada. Parts of this material are based on data and information compiled and provided by the Ontario MOH. The analyses, conclusions, opinions, and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred. References Associated Data Supplementary Materials